Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
heptaminol + deanol pidolate
- Development stage
- Unknown
- Lead developer
- Pierre Fabre
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DC158AM is an oral combination drug developed by Pierre Fabre Médicament, consisting of heptaminol hydrochloride and deanol pyroglutamate (also known as deanol pidolate). Heptaminol is a sympathomimetic amine that acts as a cardiovascular stimulant and anti-asthenic agent, while deanol pyroglutamate serves as a precursor to acetylcholine and acts as a nootropic. Historically marketed under brand names like Debrumyl and Denubil for the symptomatic treatment of general fatigue and asthenia, the combination is currently being evaluated in Phase 3 clinical trials for the treatment of fatigue in patients with Parkinson's disease.
- Brand names
- DebrumylDenubil
- Other names
- heptaminol hydrochloride + deanol pyroglutamateheptaminol hydrochloride + deanol pidolate
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on heptaminol + deanol pidolate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on heptaminol + deanol pidolate.